Asthma is one of the most prevalent chronic inflammatory respiratory diseases across the globe, with a significant increase ...

China NMPA approves GSK’s Trelegy Ellipta for use in adults with uncontrolled asthma: London, UK Saturday, January 24, 2026, 09:00 Hrs [IST] GSK plc announced that China’s Nat ...

Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart –– Recruitment ongoing for ...

Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studies ...

GSK has secured approval in China for Trelegy Ellipta as a maintenance treatment for adults with asthma, adding to its existing indication in COPD and making it the only single inhaler triple therapy ...

EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the "Company"), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

In the trial, zumilokibart demonstrated: The only treatment-emergent adverse event (TEAE) observed in more than one patient was gastroesophageal reflux disease (GERD; 2 patients). There were no Grade ...

Epinephrine is a commonly used agent for a variety of indications and clinical scenarios within the emergency department. It is commonly administered during cardiopulmonary arrest and serves as an ...

A baby was left fighting for her life with a collapsed lung after being sent home FIFTEEN times by doctors who dismissed the ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...

A baby was left fighting for her life with a collapsed lung after being sent home FIFTEEN times by doctors who dismissed the ...